TACROLIMUS (FK506) AND SIROLIMUS (RAPAMYCIN) IN COMBINATION ARE NOT ANTAGONISTIC BUT PRODUCE EXTENDED GRAFT SURVIVAL IN CARDIAC TRANSPLANTATION IN THE RAT1,2
Authors:
- Shijie QiSQShijie Qi
- Dasheng XuDXDasheng Xu
- Jiangping WuJWJiangping Wu
- William E. FitzsimmonsWFWilliam E. Fitzsimmons
- Suren N. SehgalSSSuren N. Sehgal
- Louis DumontLDLouis Dumont
- Stephan BusqueSBStephan Busque
- Pierre DalozePDPierre Daloze
- Huifang ChenHCHuifang Chen
- 1 December 1997
- journal article
- research article
- Published by Wolters Kluwer Health in Transplantation
- Vol. 64 (12) , 1853-1856
Abstract
Combined use of tacrolimus (FK506) with sirolimus (rapamycin [RAPA]) was examined in a model of vascularized heart allograft in the rat. For prevention of acute rejection, three different combinations of low doses of FK506 and RAPA from day 1 up to day 14 after transplantation produced significantly longer cardiac allograft survival than each agent alone( P <0.05). Identical results were observed in a model of reversal of ongoing acute rejection, where two combinations of low doses of FK506 and RAPA from day 4 up to day 18 after surgery also demonstrated significantly longer graft survival than each immunosuppressant alone( P <0.05). All the low-dose-treated groups in these two models presented significantly longer heart graft survival than naive controls ( P <0.05), confirming that both agents are potent immunosuppressants in the models chosen. These results also indicate that, in contrast with in vitro studies, the combined use of FK506 and RAPA in vivo did not produce antagonism, but rather had synergistic effect in prolonging the allograft survival as compared with each agent alone. It appears likely that the abundance of FKBP-12 available for binding in vivo prevents inhibitive competition of the two agents for their receptor.Keywords
This publication has 9 references indexed in Scilit:
- EFFECTS OF THE PHARMACOKINETIC INTERACTION BETWEEN ORALLY ADMINISTERED SIROLIMUS AND CYCLOSPORINE ON THE SYNERGISTIC PROLONGATION OF HEART ALLOGRAFT SURVIVAL IN RATS1Transplantation, 1996
- Rapamycin (sirolimus, rapamune)Current Opinion in Nephrology and Hypertension, 1995
- Rapamycin: A novel immunosuppressive macrolideMedicinal Research Reviews, 1994
- The immunosuppressive and toxic effects of FK-506 are mechanistically related: pharmacology of a novel antagonist of FK-506 and rapamycin.Journal of Experimental Medicine, 1992
- Cyclosporin A, FK-506, and Rapamycin: Pharmacologic Probes of Lymphocyte Signal TransductionAnnual Review of Immunology, 1992
- Is cyclophilin involved in the immunosuppressive and nephrotoxic mechanism of action of cyclosporin A?Journal of Experimental Medicine, 1991
- Two distinct signal transmission pathways in T lymphocytes are inhibited by complexes formed between an immunophilin and either FK506 or rapamycin.Proceedings of the National Academy of Sciences, 1990
- Probing Immunosuppressant Action with a Nonnatural Immunophilin LigandScience, 1990
- Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization.The Journal of Antibiotics, 1975